Commercial Lending Solutions recently closed a $32 million construction loan for a ground-up life sciences facility in Cambridge's Kendall Square, one of the nation's premier biotech clusters. The 150,000+ square foot mixed lab and flex R&D development required specialized underwriting given the unique buildout costs and tenant profile typical of emerging biotech companies.
The Deal
The sponsor needed construction financing for a purpose-built life sciences facility designed to serve the growing demand for lab space in Cambridge. The project featured specialized infrastructure including enhanced HVAC systems, reinforced floor loads for heavy equipment, and flexible lab configurations that could accommodate various biotech research functions. With strong pre-leasing activity from emerging biotech tenants, the borrower sought a lender who understood both the construction complexities and tenant credit profiles typical in the life sciences sector.
The facility's location in Kendall Square provided immediate access to MIT, Harvard, and the extensive biotech ecosystem that has made Cambridge synonymous with life sciences innovation. However, this prime positioning came with correspondingly high land costs and construction expenses that required careful underwriting.
The Challenge
Life sciences construction presents unique financing challenges that distinguish it from conventional commercial real estate development. Lab buildouts typically cost 40% to 60% more per square foot than standard office space due to specialized mechanical systems, chemical-resistant materials, and regulatory compliance requirements. Many construction lenders lack the sector expertise to accurately underwrite these costs, often resulting in inadequate funding or declined applications.
The tenant credit analysis added another layer of complexity. While the sponsor had secured pre-leasing commitments representing approximately 60% of the total square footage, the tenants were emerging biotech companies backed by venture capital rather than established corporate credits. Traditional lenders often struggle to evaluate the stability and lease-paying capacity of VC-backed biotechs, particularly those still in research phases without revenue-generating products.
Additionally, the timing mismatch between base building completion and tenant improvements created funding gaps that required careful structuring. Biotech tenants typically require 6 to 12 months for specialized lab buildouts after base building delivery, creating an extended lease-up period that impacts cash flow projections.
The Solution
We identified a national life insurance company with significant experience in life sciences real estate across major biotech markets. Their underwriting team had previously financed similar projects and understood the cost premiums associated with lab-ready infrastructure. This expertise proved crucial in achieving realistic construction budgeting and appropriate contingency reserves.
The lender structured the facility at 75% loan-to-cost with a floating rate based on SOFR plus 275 basis points. The 36-month term included two six-month extension options to accommodate potential construction delays or extended lease-up periods. Rather than traditional construction draws based solely on completion percentages, the lender implemented milestone-based funding tied to pre-leasing progress and tenant improvement commencements.
The credit analysis incorporated detailed review of each pre-leasing tenant's venture funding history, burn rates, and projected runway. The lender's life sciences team evaluated management teams, intellectual property portfolios, and development pipelines to assess lease payment sustainability. This specialized underwriting approach allowed them to credit the pre-leasing at 85% of face value rather than the 50% to 60% haircuts applied by generalist lenders.
Recognizing the extended tenant improvement period typical in life sciences, the lender structured progressive funding releases as tenants commenced buildouts and reached occupancy milestones. This approach aligned funding availability with actual cash flow generation while providing the sponsor flexibility to accommodate varying tenant timing requirements.
The Outcome
The borrower secured construction financing that accurately reflected project costs and market realities rather than forcing artificial cost reductions that would have compromised building quality or tenant suitability. The milestone-based funding structure provided adequate liquidity throughout the development process while maintaining appropriate lender oversight.
The 275 basis point spread reflected the lender's comfort with both the sponsor's experience and the specialized nature of the asset class. With 36 months plus extensions, the borrower gained sufficient time to complete construction and achieve stabilized occupancy without the pressure of premature refinancing.
Most importantly, the lender's willingness to credit pre-leasing from emerging biotech tenants enabled project feasibility that would have been impossible with conventional office underwriting standards. This specialized approach reflects the growing sophistication of capital markets participants in the life sciences sector and the recognition that Cambridge's biotech cluster represents a distinct and viable real estate market segment.